Effect of DNase on exercise capacity in cystic fibrosis

Pediatric Pulmonology

Volumn 38, Issue 1, 2004, Pages 70-74

  Barker, Michael ^a   Franke, Egbert ^a   Böhle, Martin ^a   Pfannenstiel, Claus ^a   Heimann, Gerhard ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Cystic fibrosis; Deoxyribonuclease; Exercise; Physical performance; Pulmonary function

Indexed keywords

DORNASE ALFA;

ADOLESCENT; ADULT; ARTERIAL CARBON DIOXIDE TENSION; ARTERIAL OXYGEN SATURATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFECT; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HOARSENESS; HUMAN; LUNG CAPACITY; LUNG FUNCTION; LUNG VENTILATION; LUNG VOLUME; MALE; OXYGEN CONSUMPTION; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; SORE THROAT; SPIROMETRY; SPUTUM EXAMINATION; VISCOSITY; WORKLOAD;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AEROSOLS; CHILD; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PROBABILITY; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; SPIROMETRY; TREATMENT OUTCOME;

EID: 3042643641     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.20048     Document Type: Article

References (25)

1. Potter J, Spector S, Matthews LW, Lemm J. The nucleic acids in whole pulmonary secretions from patients with cystic fibrosis, bronchiectasis and laryngectomy. Am Rev Respir Dis 1969;99: 909-916.
2. Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS. Extracellular DNA required for bacterial biofilm formation. Science 2002;295:1487.
3. Lieberman J. Dornase aerosol effects on sputum viscosity in cases of cystic fibrosis. JAMA 1968;205:114-115.
4. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase 1 reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990;87:9188-9192.
5. Hubbard RC, McElvaney NG, Birrer P, Shak S, Robinson WW, Jolley C, Wu M, Chernick MS, Crystal RG. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the sputum of cystic fibrosis. N Engl J Med 1992;326:812-815.
6. Brandt T, Breitenstein S, von der Hardt H, Tümmler B. DNA concentration and length in sputum of patients with cystic fibrosis during inhalation with recombinant DNase. Thorax 1995;50: 880-882.
7. Ramsey BW, Astley SJ, Aitken ML, Burke W, Colin AA, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Schidlow DV, et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993;148:145-151.
8. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME, for the Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-642.
9. Shah PL, Scott SF, Fuchs HJ, Geddes DM, Hodson ME. Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I. Thorax 1995;50:333-338.
10. Harms HK, Matouk E, Tournier G, von der Hardt H, Weller PH, Romano L, Heijerman HGM, FitzGerald MX, Richard D, Strandvik B, Kolbe J, Kraemer R, Michalsen H, on behalf of the DNase International Study Group. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. Pediatr Pulmonol 1998;26: 155-161.
11. Johnson CA, Butler SM, Konstan MW, Breen TJ, Morgan WJ. Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. J Pediatr 1999; 134:734-739.
12. Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, Wohl ME, Konstan MW. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001;139:813-820.
13. Innes JA. DNase in cystic fibrosis: the challenge of assessing response and maximising benefit. Thorax 1998;53:1003-1004.
14. Cobos N, Dnaes I, Gartner S, Gonzalez M, Linan S, Arnau JM. DNase use in the daily care of cystic fibrosis: who benefits from it and to what extent? Eur J Pediatr 2000;159:176-181.
15. Davies J, Trindade MT, Wallis C, Rosenthal M, Crawford O, Crawford O, Bush A. Retrospective review of the effects of rhDNase in children with cystic fibrosis. Pediatr Pulmonol 1997; 23:243-248.
16. Bradley J, McAllister O, Elborn S. Pulmonary function, inflammation, exercise capacity and quality of life in cystic fibrosis. Eur Respir J 2001;17:712-715.
17. Böllert FG, Paton JY, Marshall TG, Calvert J, Greening AP, Innes JA. Recombinant DNase in cystic fibrosis: a protocol for targeted introduction through n-of-1 trials. Scottish Cystic Fibrosis Group. Eur Respir J 1999;13:107-113.
18. Kromeyer-Hauschild K, Wabitsch M, Kunze D, Geiss HC, Hesse V, von Hippel A, Jaeger U, Johnsen D, Korte W, Menner K, Müller G, Müller JM, Niemann-Pilatus A, Remer T, Schaefer F, Wittchen HU, Zabransky S, Zellner K, Ziegler A, Hebebrand J. Percentiles of body mass index in children and adolescents evaluated from different regional German studies. Monatsschr Kinderheilkd 2001;149:807-818.
19. Suri R, Metcalfe C, Lees B, Grieve R, Flather M, Normand C, Thompson S, Bush A, Wallis C. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001; 358:1316-1321.
20. Robinson M, Hemming AL, Moriarty C, Eberl S, Bye PTP. Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis. Pediatr Pulmonol 2000;30:16-24.
21. Godfrey S, Mearns M. Pulmonary function and response to exercise in cystic fibrosis. Arch Dis Child 1971;46:144-151.
22. Nixon PA, Orenstein DM, Kelsey SF, Doershuk CF. The prognostic value of exercise testing in cystic fibrosis. N Engl J Med 1992;327:1785-1788.
23. Kadikar A, Maurer J, Kesten S. The six-minute walk test: a guide to assessment for lung transplantation. J Heart Lung Transplant 1997;16:313-319.
24. McKone EF, Barry SC, FitzGerald MX, Gallagher CG. Repeat-ability of maximal exercise ergometer testing in patients with cystic fibrosis. Chest 1999;116:363-368.
25. Jones AP, Wallis CE. Recombinant human deoxyribonuclease for cystic fibrosis. Cochrane Database Syst Rev 2003;3. CD001127.